Floatz logo

bnt162b2

Chronic Disease

National and Kapodistrian University of AthensvaccineDormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Chronic Disease cohort.

Asset / SponsorPhaseRating
Velaglucerase Alfa
Shaare Zedek Medical Center
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
RIVER Foundation
Phase 4BB
Asenapine
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Phase 4BB
NEPENTHE
Federal University of Paraíba
Phase 4BB
Naltrexone
Pfizer
Phase 4BB

View all 39 →

Same molecule, other indications

bnt162b2 is also rated in:

Multiple SclerosisDormant
CC
Indicative ·
44 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
43 / 100
View asset →
rheumatoid arthritisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →